Source content
FAA Guide for Aviation Medical Examiners · Version 10/28/2026 · page 693
AASI for Venous Thromboembolism (VTE) - Deep Venous
Thrombosis (DVT), Pulmonary Embolism (PE), and/or
Hypercoagulopathies
(Updated 03/27/2024)
AME Assisted Special Issuance (AASI) is a process that provides AMEs the ability to re-issue
an airman medical certificate under the provisions of an Authorization for Special Issuance of a
Medical Certificate (Authorization) to an applicant who has a medical condition that is
disqualifying under Title 14 of the Code of Federal Regulations (14 CFR) part 67.
An FAA physician provides the initial certification decision and grants the Authorization in
accordance with 14 CFR § 67.401. The Authorization letter is accompanied by attachments
that specify the information that treating physician(s) must provide for the re-issuance
determination. If this is a first-time issuance of an Authorization for the above
disease/condition, and the applicant has requisite medical information necessary for a
determination, the AME must defer and submit all of the documentation to the AMCD or RFS
for the initial determination.
AMEs may re-issue an airman medical certificate under the provisions of an Authorization for
Special Issuance, if the applicant provides the following:
• A valid Authorization for Special Issuance granted by the FAA;
• A summary of the applicant’s medical condition since the last FAA medical examination,
including a statement regarding any further episodes of VTE (DVT, PE) or other
complication of hypercoagulopathy (see below*), future treatment plan, and prognosis;
• The name and dosage of all medication(s) used for treatment and/or prevention with
comment regarding side effects, if any; and
• If using Jantoven (warfarin), obtain a minimum of monthly International Normalized
Ratio (INR) results for the immediate prior 6 months (see below*); and
• If using other types of anticoagulants such as NOAC/DOAC (i.e. Xarelto, Eliquis,
Pradaxa, Savaysa, etc.), the airman should obtain a statement from their
treating/prescribing physician with details of the underlying condition, tolerance of the
medication to include the presence or absence of side effects, any bleeding episodes
requiring medical attention, and any occurrence/recurrence of deep vein thrombosis or
pulmonary embolism.
*The AME must defer to the AMCD or Region if:
• If using Jantoven (warfarin) and more than 20% of INR values are <2.0 or >3.0; or
• If applicant experienced any side effects or bleeding episodes requiring medical
attention; or
• The applicant develops emboli, thrombosis, bleeding, or any other cardiac or neurologic
condition previously not diagnosed or reported.
Shown as extracted from the FAA PDF, without paraphrasing. Tables and forms may lose their layout. Underlined references open the Guide location they name.
FAA Guide for Aviation Medical Examiners, Version 10/28/2026, page 693. AME Copilot is an independent reference tool, not affiliated with or endorsed by the FAA. The FAA AME Guide is the authoritative source.